{"filing": {"accession": "0001493152-26-044208", "cik": "0001054102", "ticker": "IDXG", "company_name": "INTERPACE BIOSCIENCES, INC.", "form_type": "S-1", "filing_type": "S-1", "filing_date": "2026-09-25", "accepted_datetime": null, "acceptance_datetime": null, "accepted_at": null, "primary_doc_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315226044208/0001493152-26-044208-index.htm", "filing_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315226044208/0001493152-26-044208-index.htm", "period_of_report": null}, "html_url": "/api/filings/000149315226044208/stream", "exhibits": [{"exhibit_number": "1.1", "exhibit_type": "1", "description": "Form of Underwriting Agreement by and between Interpace Biosciences, Inc. and Lake Street Capital Markets, LLC (filed herewith).", "filename": "ex1-1.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315226044208/ex1-1.htm", "category": "debt", "incorporated_by_reference": false}, {"exhibit_number": "3.2", "exhibit_type": "3", "description": "Amended and Restated Certificate of Incorporation, dated August 20, 2026 (filed herewith).", "filename": "ex3-2.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315226044208/ex3-2.htm", "category": "incorporation", "incorporated_by_reference": false}, {"exhibit_number": "3.3", "exhibit_type": "3", "description": "Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated August 25, 2026 (filed herewith).", "filename": "ex3-3.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315226044208/ex3-3.htm", "category": "incorporation", "incorporated_by_reference": false}, {"exhibit_number": "5.1", "exhibit_type": "5", "description": "Opinion of McDermott Will & Schulte LLP (filed herewith).", "filename": "ex5-1.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315226044208/ex5-1.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "23.1", "exhibit_type": "23", "description": "Consent of EisnerAmper, LLP (filed herewith).", "filename": "ex23-1.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315226044208/ex23-1.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "23.2", "exhibit_type": "23", "description": "Consent of McDermott Will & Schulte LLP (included in Exhibit 5.1 filed herewith).", "filename": "ex5-1.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315226044208/ex5-1.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "2.1", "exhibit_type": "2", "description": "Asset Purchase Agreement, dated August 13, 2014, by and between Interpace Diagnostics, LLC and Asuragen, Inc., incorporated by reference to Exhibit 2.2 of the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 5, 2014.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000105410214000050/exhibit22assetpurchaseagre.htm", "category": "other", "incorporated_by_reference": true}, {"exhibit_number": "3.1", "exhibit_type": "3", "description": "Amended and Restated Bylaws of Interpace Biosciences, Inc., incorporated by reference to Exhibit 3.2 of the Company\u2019s Current Report on Form 8-K, filed with the SEC on November 14, 2019.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315219017468/ex3-2.htm", "category": "incorporation", "incorporated_by_reference": true}, {"exhibit_number": "4.1", "exhibit_type": "4", "description": "Description of Securities, incorporated by reference to Exhibit 4.1 of the Company\u2019s Annual Report on Form 10-K, filed with the SEC on April 1, 2021.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315221007629/ex4-1.htm", "category": "debt", "incorporated_by_reference": true}, {"exhibit_number": "4.2", "exhibit_type": "4", "description": "Specimen Certificate Representing the Common Stock, incorporated by reference to Exhibit 4.1 of the Company\u2019s Registration Statement on Form S-3 (File No. 333-227728), filed with the SEC on October 5, 2018.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315218014198/ex4-1.htm", "category": "debt", "incorporated_by_reference": true}, {"exhibit_number": "10.1", "exhibit_type": "10", "description": "Amended and Restated 2004 Stock Award and Incentive Plan, incorporated by reference to Annex A of the Company\u2019s definitive proxy statement, filed with the SEC on August 14, 2017.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315217009064/def14a.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.2", "exhibit_type": "10", "description": "Form of Non-Qualified Stock Option Agreement, incorporated by reference to Exhibit 10.3 of the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the SEC on May 15, 2018.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315218007054/ex10-3.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.3", "exhibit_type": "10", "description": "Form of Incentive Stock Option Agreement, incorporated by reference to Exhibit 10.4 of the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the SEC on May 15, 2018.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315218007054/ex10-4.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.4", "exhibit_type": "10", "description": "Interpace Diagnostics Group, Inc. 2019 Equity Incentive Plan, incorporated by reference to Exhibit 4.1 of the Company\u2019s quarterly report on Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on November 14, 2019.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315219017510/ex4-1.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.5", "exhibit_type": "10", "description": "Amendment to the Interpace Biosciences, Inc. 2019 Equity Incentive Plan, incorporated by reference to Exhibit 10.8 of the Company\u2019s quarterly report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on June 26, 2020.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315220011860/ex10-8.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.6", "exhibit_type": "10", "description": "Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the 2019 Equity Incentive Plan, incorporated by reference to Exhibit 4.3 of the Company\u2019s quarterly report on Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on November 14, 2019.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315219017510/ex4-3.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.7", "exhibit_type": "10", "description": "Form of Interpace Biosciences, Inc. 2019 Equity Incentive Plan Restricted Stock Unit And Restricted Stock Unit Agreement, incorporated by reference to Exhibit 10.9 of the Company\u2019s quarterly report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on June 26, 2020.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315220011860/ex10-9.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.8", "exhibit_type": "10", "description": "Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Equity Incentive Plan, incorporated by reference to Exhibit 4.4 of the Company\u2019s quarterly report on Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on November 14, 2019.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315219017510/ex4-4.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.9", "exhibit_type": "10", "description": "Incentive Stock Option Agreement between Interpace Diagnostics Group, Inc. and Jack E. Stover, incorporated by reference to Exhibit 10.1 of the Company\u2019s Current Report on Form 8-K, filed with the SEC on October 20, 2016.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000143774916040018/ex10-1.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.10", "exhibit_type": "10", "description": "Employment Agreement, dated November 23, 2020, between Thomas W. Burnell and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.1 of the Company\u2019s Current Report on Form 8-K, filed with the SEC on November 25, 2020.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315220022492/ex10-1.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.11", "exhibit_type": "10", "description": "Employment Agreement, dated July 24, 2023, between Christopher McCarthy and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.1 of the Company\u2019s Current Report on Form 8-K, filed with the SEC on August 2, 2023.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315223026343/ex10-1.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.12", "exhibit_type": "10", "description": "Form of Indemnification Agreement by and between Interpace Diagnostics Group, Inc. and its directors and executive officers, incorporated by reference to Exhibit 10.1 of the Company\u2019s Current Report on Form 8-K, filed with the SEC on August 8, 2016.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000143774916036763/ex10-1.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.13", "exhibit_type": "10", "description": "Form of Indemnification Agreement by and between Interpace Biosciences, Inc. and Indemnitee, incorporated by reference to Exhibit 10.2 of the Company\u2019s Current Report on Form 8-K, filed with the SEC on January 17, 2020.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315220000711/ex10-2.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.14", "exhibit_type": "10", "description": "2026 Employee Stock Purchase Plan, incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-8, filed with the SEC on September 17, 2026.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315226043106/ex4-2.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.15", "exhibit_type": "10", "description": "Agreement, dated January 21, 2022, between Dr. Vijay Aggarwal and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.1 of the Company\u2019s Current Report on Form 8-K, filed with the SEC on January 27, 2022.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315222002401/ex10-1.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.16", "exhibit_type": "10", "description": "Lease Agreement, dated March 31, 2017, by and between Saddle Lane Realty, LLC and the Company, incorporated by reference to Exhibit 10.53 of the Company\u2019s Registration Statement on Form S-1 (333-218140), as amended on June 13, 2017.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315217006543/ex10-53.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.17", "exhibit_type": "10", "description": "First Amendment, dated September 26, 2017, by and between Saddle Lane Realty, LLC and Interpace Diagnostics Corporation, incorporated by reference to Exhibit 10.36 of the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315220006897/ex10-36.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.18", "exhibit_type": "10", "description": "Amendment No. 2 to Lease, dated March 15, 2018, between Saddle Lane Realty, LLC and Interpace Diagnostics Corporation, incorporated by reference to Exhibit 10.45 of the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 23, 2018.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315218003786/ex10-45.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.19", "exhibit_type": "10", "description": "Fourth Lease Amendment by and between Interpace Biosciences, Inc. and Saddle Lane Realty, LLC, dated as of October 31, 2022, incorporated by reference to Exhibit 10.1 of the Company\u2019s Current Report on Form 8-K filed with the SEC on November 4, 2022.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315222030690/ex10-1.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.20", "exhibit_type": "10", "description": "Amendment to the Interpace Biosciences, Inc. 2019 Equity Incentive Plan, incorporated by reference to Exhibit 10.1 of the Company\u2019s Current Report on Form 8-K, filed with the SEC on November 15, 2022.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315222032503/ex10-1.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.21", "exhibit_type": "10", "description": "Amended and Restated Investor Rights Agreement, dated as of October 10, 2024, by and among Interpace Biosciences, Inc., 1315 Capital II, L.P. and Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 10.2 of the Company\u2019s Current Report on Form 8-K, filed with the SEC on October 15, 2024.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315224041144/ex10-2.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.22", "exhibit_type": "10", "description": "2026 Equity Incentive Plan, incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8, filed with the SEC on September 17, 2026.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315226043106/ex4-1.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.23", "exhibit_type": "10", "description": "Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the 2026 Equity Incentive Plan, incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-8, filed with the SEC on September 17, 2026.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315226043106/ex4-3.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.24", "exhibit_type": "10", "description": "Form of Stock Option Grant Notice and Stock Option Agreement under the 2026 Equity Incentive Plan, incorporated by reference to Exhibit 4.4 to the Registration Statement on Form S-8, filed with the SEC on September 17, 2026.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315226043106/ex4-4.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "21.1", "exhibit_type": "21", "description": "Subsidiaries of the Registrant, incorporated by reference to Exhibit 21.1 of the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1054102/000149315220006897/ex21-1.htm", "category": "other", "incorporated_by_reference": true}], "sections": [{"section_name": "part_2", "section_title": "Part II", "start_position": 133774, "end_position": 154703}], "tables": [{"table_index": 0, "table_type": "text", "caption": null, "header_text": "Delaware384122-2919486"}, {"table_index": 2, "table_type": "text", "caption": null, "header_text": "Large\n accelerated filer \u2610Accelerated\n filer \u2610"}, {"table_index": 4, "table_type": "financial", "caption": null, "header_text": "Per\n shareTotal"}, {"table_index": 8, "table_type": "financial", "caption": null, "header_text": "MARKET AND INDUSTRY DATA3"}, {"table_index": 13, "table_type": "text", "caption": null, "header_text": "Cancer TypeEstimated New CasesEstimated Deaths"}, {"table_index": 17, "table_type": "text", "caption": null, "header_text": "\u25ccContinuing\n support of an internal managed care team;"}, {"table_index": 20, "table_type": "text", "caption": null, "header_text": "\u25cfExploring\n partnering or other opportunities to acquire new technologies and products; and"}, {"table_index": 23, "table_type": "financial", "caption": null, "header_text": "2022202320242025"}, {"table_index": 24, "table_type": "text", "caption": null, "header_text": "2022202320242025"}, {"table_index": 26, "table_type": "text", "caption": null, "header_text": "2025"}, {"table_index": 29, "table_type": "financial", "caption": null, "header_text": "Common\n stock offered by us$20,000,000\n of common stock."}, {"table_index": 30, "table_type": "text", "caption": null, "header_text": "\u25cf49,244\n shares issuable under our 2019 Equity Incentive Plan (including 10,134 shares under the 2004 Stock Award and Incentive Plan) upon\n the exercise of outstanding stock options, with a weighted a"}, {"table_index": 36, "table_type": "financial", "caption": null, "header_text": "\u25cfon\n an actual basis;"}, {"table_index": 37, "table_type": "text", "caption": null, "header_text": "As of June 30, 2026"}, {"table_index": 38, "table_type": "text", "caption": null, "header_text": "\u25cf49,244\n shares issuable under our 2019 Equity Incentive Plan (including 10,134 shares under the 2004 Stock Award and Incentive Plan) upon\n the exercise of outstanding stock options, with a weighted a"}, {"table_index": 40, "table_type": "text", "caption": null, "header_text": "Assumed public offering price per share of common stock$6.47"}, {"table_index": 41, "table_type": "text", "caption": null, "header_text": "\u25cf49,244\n shares issuable under our 2019 Equity Incentive Plan (including 10,134 shares under the 2004 Stock Award and Incentive Plan) upon\n the exercise of outstanding stock options, with a weighted a"}, {"table_index": 53, "table_type": "text", "caption": null, "header_text": "\u25cfrestricting\n dividends on the common stock;"}, {"table_index": 54, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n acquisition of us by means of a tender offer;"}, {"table_index": 56, "table_type": "text", "caption": null, "header_text": "\u25cfStockholder\n meetings. Under our Amended and Restated Certificate of Incorporation, only the chairperson of our Board of Directors, our chief\n executive officer or the Board of Directors by majority "}, {"table_index": 57, "table_type": "text", "caption": null, "header_text": "\u25cfprior\n to such time, the board of directors of the corporation approved either the business combination or the transaction which resulted\n in the stockholder becoming an interested stockholder;"}, {"table_index": 58, "table_type": "text", "caption": null, "header_text": "\u25cfany\n person that is the owner of 15% or more of the outstanding voting stock of the corporation, or is an affiliate or associate of the\n corporation and was the owner of 15% or more of the outstandin"}, {"table_index": 60, "table_type": "text", "caption": null, "header_text": "Name of Beneficial OwnerNumber\n of Shares Beneficially Owned(1)Percent of Shares Outstanding"}, {"table_index": 62, "table_type": "text", "caption": null, "header_text": "(1)Beneficial\n ownership and percentage ownership are determined in accordance with the rules and regulations of the SEC and include voting or investment\n power with respect to shares of stock. This i"}, {"table_index": 64, "table_type": "text", "caption": null, "header_text": "UnderwriterNumber\n of Shares"}, {"table_index": 65, "table_type": "financial", "caption": null, "header_text": "Per\n ShareTotal\n withno Over-AllotmentTotal\n withOver-Allotment"}, {"table_index": 69, "table_type": "exhibit_index", "caption": null, "header_text": "\u25cfOur\n Annual Report on Form 10-K for the fiscal year December 31, 2025 filed with the SEC onMarch 30, 2026, as amended onApril 30, 2026."}, {"table_index": 71, "table_type": "financial", "caption": null, "header_text": "Amount"}, {"table_index": 72, "table_type": "text", "caption": null, "header_text": "\u25cfany\n breach of the director\u2019s or officer\u2019s duty of loyalty to the Registrant or its stockholders;"}, {"table_index": 74, "table_type": "exhibit_index", "caption": null, "header_text": "ExhibitNo.Description"}, {"table_index": 76, "table_type": "exhibit_index", "caption": null, "header_text": "10.11*Employment Agreement, dated July 24, 2023, between Christopher McCarthy and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.1 of the Company\u2019s Current Report on Form 8-K, fi"}, {"table_index": 78, "table_type": "text", "caption": null, "header_text": "(1)To\n file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:"}, {"table_index": 79, "table_type": "text", "caption": null, "header_text": "(i)any\n preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule\n 424;"}, {"table_index": 81, "table_type": "text", "caption": null, "header_text": "INTERPACE\n BIOSCIENCES, INC."}, {"table_index": 82, "table_type": "text", "caption": null, "header_text": "/s/ Thomas W. BurnellPresident,\n Chief Executive Officer and DirectorSeptember\n 24, 2026"}], "exhibits_pending": false, "cdn_html": true, "response_time_ms": 38}